Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 449884 (ISIS-GCGRRX) effect on hepatic lipid and glycogen in type 2 diabetes on metformin
2015-003337-10Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Sep 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ISIS 449884 with Placebo (2 arms). Primary endpoint: Pharmacodynamic effects on hepatic lipid and glycogen content. Started Sep 2015; status: completed.
02
Drugs
ISIS 449884
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-003337-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003337-10.